Mytesi is Napo's FDA-approved drug product indicated for the symptomatic relief of noninfectious
diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).
Schachner noted that the differential diagnosis of noninfectious
, usually benign neonatal vesiculopustular lesions includes acropustulosis of infancy; eosinophilic pustular folliculitis; erythema toxicum neonatorum; miliaria crystallina, rubra, or profunda; transient neonatal pustular melanosis; and neonatal sucking blisters.
Singer, M.D., Ph.D., from the University of Michigan in Ann Arbor, and colleagues compared brain tissue of patients who died of sepsis to that of patients who died of noninfectious
PEACHTREE is the first -pivotal phase 3 clinical trial of a drug candidate for noninfectious
uveitis in which a best corrected visual acuity measure is the primary efficacy endpoint.
To improve the usability, availability, quality, and timeliness of surveillance data as part of the CDC Surveillance Strategy (1), CDC now provides users a convenient way to access notifiable infectious and noninfectious
disease data through the National Notifiable Diseases Surveillance System (NNDSS) website.
IVT sirolimus, being evaluated as a potential treatment for adults with noninfectious
uveitis of the posterior segment (intermediate, posterior, and panuveitis), is a locally-administered, non-steroidal immunoregulator that has been investigated for the resolution of intraocular inflammation associated with noninfectious
uveitis of the posterior segment.
The National Institute for Health and Care Excellence (NICE) has issued guidance recommending the use of adalimumab for the treatment of noninfectious
(Jaguar) and Napo began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialisation of Mytesi, which is approved by the US FDA for the symptomatic relief of noninfectious
diarrhea in adults with HIV/AIDS on antiretroviral therapy.
"EARLY IDENTIFICATION of these noninfectious
events is important as standard antiexacerbation therapies including systemic corticosteroids and antibiotics are unlikely to be clinically useful for these etiologies and, importantly, may result in delays in the diagnosis and treatment of noninfectious
causes of exacerbation such as acute coronary syndromes or congestive heart failure, leading to poor clinical outcomes.
HUMIRA targets and helps block TNF-alpha, a specific source of inflammation that can have a role in uveitis.(13,14) The approval is based on results from two pivotal Phase 3 studies VISUAL-I and VISUAL-II, and also extension study VISUAL-III, which demonstrated that patients with active and controlled noninfectious
intermediate, posterior and panuveitis treated with HUMIRA had a significantly lower risk for treatment failure (a combination of uveitic flare and decrease in visual acuity), compared to placebo.
However, over the years, the discovery and use of antiretroviral therapy has increased life expectancy for HIV-infected persons, and the spectrum of infectious and noninfectious
pulmonary complications has changed.